Carisma Therapeutics Inc CARM.OQ CARM.O is expected to show a rise in quarterly revenue when it reports results on March 31 (estimated) for the period ending December 31 2024
The Philadelphia Pennsylvania-based company is expected to report a 26.4% increase in revenue to $5.42 million from $4.29 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
LSEG's mean analyst estimate for Carisma Therapeutics Inc is for a loss of 16 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Carisma Therapeutics Inc is $6.50, above its last closing price of $0.36.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.28 | -0.26 | -0.31 | Missed | -19.2 |
Jun. 30 2024 | -0.31 | -0.30 | -0.27 | Beat | 9.2 |
Mar. 31 2024 | -0.47 | -0.43 | -0.46 | Missed | -6.4 |
Dec. 31 2023 | -0.55 | -0.52 | Beat | 5.9 | |
Sep. 30 2023 | -0.56 | -0.57 | -0.53 | Beat | 7 |
Jun. 30 2023 | -0.60 | -0.60 | -0.49 | Beat | 17.9 |
Mar. 31 2023 | -0.89 | -0.89 | -1.93 | Missed | -116.9 |
Dec. 31 2022 | -2.20 | -2.20 | -0.80 | Beat | 63.6 |
This summary was machine generated March 28 at 13:00 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。